comparemela.com

Page 5 - Ann Ondish News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ADC Therapeutics SA: ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents

Opportunity to enhance outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphoma First arm of trial to evaluate ZYNLONTA in combination with polatuzumab vedotin ADC Therapeutics

New jerseyUnited statesCity ofUnited kingdomLausanne biopMary ann ondishEugenia litzJoseph camardoAmanda hamiltonExchange commissionCompany on twitterDrug administrationChief medical officerSan francisco bay areaAnn ondish

ADC Therapeutics SA: ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer

Seasoned life sciences executive brings extensive business development expertise ADC Therapeutics SA (NYSE: ADCT) announced today it has appointed industry veteran David Gilman to the new role of

New jerseyUnited statesCity ofUnited kingdomLausanne biopMary ann ondishDavid gilmanEugenia litzAmanda hamiltonFrankel group huron consultingCompany on twitterBusiness development for novartis oncologyUniversity of texasUniversity of chicagoChief business strategy officerChief executive officer ameet mallik

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Overall response rate of 70.1% and complete response rate of 33.3% in heavily pretreated patients; median duration of response of 13.7 months Safety profile substantially consistent with prior findings

New jerseyUnited statesCity ofUnited kingdomLausanne biopLoncastuximab tesirineCamidanlumab tesirine camiEugenia litzCarmelo carlo stellaMary ann ondishAmanda hamiltonJoseph camardoHumanitas universityCompany on twitterEuropean hematology associationHumanitas research hospital

ADC Therapeutics SA: ADC Therapeutics to Present at the Jefferies Healthcare Conference

ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8,

New jerseyUnited statesCity ofUnited kingdomLausanne biopMary ann ondishEugenia litzAmanda hamiltonCompany on twitterChief executive officerAmeet mallikJefferies healthcare conferenceEvents presentationsSan francisco bay areaAnn ondish

ADC Therapeutics SA: ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

Oral presentation of pivotal Phase 2 clinical trial of Cami in relapsed or refractory Hodgkin lymphoma ZYNLONTA diffuse large B-cell lymphoma data highlighted in several abstracts ADC Therapeutics

United statesNew jerseyCity ofUnited kingdomLausanne biopLoncastuximab tesirineCamidanlumab tesirine camiEugenia litzCarmelo carlo stellaCamidanlumab tesirineMary ann ondishAmanda hamiltonJoseph camardoHumanitas universityCompany on twitterEuropean hematology association

vimarsana © 2020. All Rights Reserved.